CD147-specific chimeric antigen receptor T cells effectively inhibit T cell acute lymphoblastic leukemia
Authors:
- 31 May 2022
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 542, 215762
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81621001, 81874155, 82002940, 82130084)
- Fourth Military Medical University
- National Key Research and Development Program of China (2017YFA0104500)
This publication has 43 references indexed in Scilit:
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cellsLeukemia, 2015
- A T-cell–directed chimeric antigen receptor for the selective treatment of T-cell malignanciesBlood, 2015
- A chimeric antibody targeting CD147 inhibits hepatocellular carcinoma cell motility via FAK-PI3K-Akt-Girdin signaling pathwayClinical & Experimental Metastasis, 2014
- The Biological Function and Clinical Utilization of CD147 in Human Diseases: A Review of the Current Scientific LiteratureInternational Journal of Molecular Sciences, 2014
- Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenograftsLeukemia, 2013
- Human T-leukemia and T-lymphoma express glutamate receptor AMPA GluR3, and the neurotransmitter glutamate elevates the cancer-related matrix-metalloproteinases inducer CD147/EMMPRIN, MMP-9 secretion and engraftment of T-leukemiain vivoLeukemia & Lymphoma, 2009
- Molecular pathogenesis of T-cell leukaemia and lymphomaNature Reviews Immunology, 2008
- Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia XenograftsClinical Cancer Research, 2007
- Emmprin, a cell surface inducer of matrix metalloproteinases (MMPs), is expressed in T‐cell lymphomasThe Journal of Pathology, 2004